CoChat

The Association Between Obesity and the 5-Year Prevalence of Morbidity and Mortality Among Adults with Type 2 Diabetes

Open access

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: This retrospective claims database study examined the prevalence of mortality and morbidity among adults with type 2 diabetes (T2D) and obesity. METHODS: The study used deidentified data from 2007 to 2021 from the Optum® Market Clarity Dataset. A cohort of adults with T2D and obesity were identified, and age- and sex-adjusted prevalence rates were calculated for mortality, a composite cardiovascular outcome (CCO), a composite microvascular outcome (CMO), and other complications. Results were examined overall and by obesity class (class 1, class 2, and class 3). RESULTS: For the 15,970 adults included in the study, the prevalence of CCO and CMO after 5 years was 15.3% and 60.7%, respectively. The 5-year prevalence of mortality was 10.9%. There were statistically significant differences in prevalence rates by obesity class, with obesity class 3 associated with higher rates of morbidity and mortality compared to obesity classes 1 or 2. Specifically, after 5 years, the prevalence of mortality was 9.4%, 10.3% and 13.6% for obese classes 1, 2 and 3, respectively (P < 0.05 between class 3 and class 2 or 1). Similarly, For obesity classes 1, 2 and 3, the 5-year prevalence of CCO was 13.0%, 14.5% and 18.4% and the rates for CMO were 58.0%, 57.9% and 64.8%, respectively (both P < 0.05 between class 3 and class 2 or 1). Regarding other complications, differences in the prevalence of atherosclerotic cardiovascular disease (ASCVD) and obstructive sleep apnea (OSA) were statistically significantly higher with increasing obesity class. CONCLUSIONS: The results indicate that for a cohort of adults with T2D and obesity, obesity class 3 is associated with significantly higher mortality and morbidity, including CCO, CMO, ASCVD and OSA. These findings suggest that treatment which reduces obesity among individuals with T2D may have significant health benefits, although additional studies are needed to confirm the results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-023-01384-7

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow chart of inclusion–exclusion criteria and sample size. BMI Body mass index, HbA1c glycated hemoglobin, T2D type 2 diabetes
Fig. 1 Flow chart of inclusion–exclusion criteria and sample size. BMI Body mass index, HbA1c glycated hemoglobin, T2D type 2 diabetesCC BY-NC · PubMed Central
Fig. 2 The 5-year age- and sex-adjusted prevalence of morality by obesity class. Obes1 Class 1 obesity: 30 kg/m2 < body mass index (BMI) < 35 kg/m2, Obes2 class 2 obesity: 35 kg/m2 < BMI < 40 kg/m2. Obes3 class 3 obesity: BMI ≥ 40 kg/m2
Fig. 2 The 5-year age- and sex-adjusted prevalence of morality by obesity class. Obes1 Class 1 obesity: 30 kg/m2 < body mass index (BMI) < 35 kg/m2, Obes2 class 2 obesity: 35 kg/m2 < BMI < 40 kg/m2. Obes3 class 3 obesity: BMI ≥ 40 kg/m2CC BY-NC · PubMed Central
Fig. 3 The 5-year age- and sex-adjusted prevalence of composite cardiovascular outcome by obesity class
Fig. 3 The 5-year age- and sex-adjusted prevalence of composite cardiovascular outcome by obesity classCC BY-NC · PubMed Central
Fig. 4 The 5-year age- and sex-adjusted prevalence of composite microvascular outcome by obesity class
Fig. 4 The 5-year age- and sex-adjusted prevalence of composite microvascular outcome by obesity classCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 1

  1. Sharma B, John S. Nonalcoholic Steatohepatitis (NASH). In: StatPearls. Treasure Island: StatPearls Publishing. 2022 [updated 2021 Sep 21]. https://www.ncbi.nlm.nih.gov/books/NBK470243. Accessed cited 17 Jun 2022.

Cited by

See all 32

Metadata

Authors
Boye, K. S., Ford, J. H., Thieu, V. T., Lage, M. J., & Terrell, K. A.
Affiliations
Eli Lilly (United States) (US)
Corresponding author
Lage, Maureen J.
Venue
Diabetes Therapy
Published
2023-02-23
Volume
14
Issue
4
Pages
709-721
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W4321611198
Cited by
26
References
33
Citations by year
2026: 6 · 2025: 12 · 2024: 5 · 2023: 3
FWCI
5.33
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
type 2 diabetes, obesity, obesity class, mortality, cardiovascular complications, microvascular complications, atherosclerotic cardiovascular disease, obstructive sleep apnea, diabetes complications, obesity treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Association Between Obesity and the 5-Year Prevalence of Morbidity and Mortality Among Adults with Type 2 Diabetes. https://app.cochat.ai/papers/10.1007/s13300-023-01384-7
The paper
Boye, K. S., Ford, J. H., Thieu, V. T., Lage, M. J., & Terrell, K. A. (2023). The Association Between Obesity and the 5-Year Prevalence of Morbidity and Mortality Among Adults with Type 2 Diabetes. Diabetes Therapy. https://doi.org/10.1007/s13300-023-01384-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.